abaloparatide injection
for subcutaneous use Initial U.S. Approval: 2017

As specified in the prescribing information, abaloparatide injection is indicated for the treatment of osteoporosis. TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Facts about abaloparatide injection

Approval Date: 2017
Proprietary Name: TYMLOS (abaloparatide) injection
Active Ingredient(s): abaloparatide
FDA-approved use: osteoporosis
Dosage Form: Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcL of sterile, clear, colorless solution
Medicine Approved By: US FDA
Manufacturer: Radius Health, Inc.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “abaloparatide injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.